In Spain, the Science, Technology and Innovation Act 14/2011 guides the implementation of public policy on science, technology and innovation, and the organisation of actions to foster and coordinate scientific and technical innovation. The Spanish Strategy for Science and Technology and Innovation 2013-20 defines the general scope and main objectives, while the State Plan for Scientific and Technical Research and Innovation specifies the operational tools and funding instruments required to implement research and development (R&D) activities. The new State Plan for Scientific and Technical Research and Innovation 2017-20, drafted by the Ministry of Economy, Industry and Competitiveness, has been submitted for public consultation. Projects are funded by the general budget of the central government, through public tenders or calls. The new State Plan for Scientific and Technical Research and Innovation 2017-20 will be implemented through four programmes.
The Government Delegation for the National Plan on Drugs is responsible for directing drug-related research activities. The Spanish Observatory on Drugs and Addictions collects, analyses and disseminates statistical and epidemiological data on drug use. Furthermore, the Government Delegation for the National Plan on Drugs channels funds to research projects carried out both by public and non-profit-making private R&D centres. Nevertheless, universities and research networks are the main actors undertaking drug-related research. Priority areas include basic clinical, social, epidemiological and methodological research. Spanish strategies on drugs have put special emphasis on the promotion of research; on systematic evaluation of programmes and actions; and on the use of evidence to support the design of policies and programmes. National scientific journals and specialised websites are the main channels for disseminating drug-related research findings. The EU-funded Ibero-American Library on Drugs and Drug Addiction had been established, and international cooperation in drug research is in place (e.g. with the US National Institute on Drug Abuse).